Skip to main content
Premium Trial:

Request an Annual Quote

NuGen Signs Marketing Agreements with Asian, European Partners; Opens European Sales Office

NEW YORK, Feb. 2 (GenomeWeb News) - NuGen Technologies has signed agreements with MediBic of Japan and TouchDown Biomarketing in Europe to help it market and sell its RNA-amplification products in Asia and Europe, respectively, the company said yesterday.


San Carlos, Calif.-based NuGen also said it has opened a sales office in Europe, which will be managed by TouchDown. NuGen's European sales team will work with TouchDown to launch the company's RNA-amplification systems in the European market.


MediBic, a Japanese life sciences and pharmacogenomics consulting company, will help NuGen introduce its Ovation RNA-amplification products throughout Asia.


TouchDown is based in Gendt, The Netherlands, and MediBic is located in Tokyo.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.